Dermal Papilla Cells and Hair Cloning: Where the Research Stands

Dermal papilla cells help direct hair-follicle growth and cycling, which makes them an important focus of hair-cloning research. But studying these cells is not the same as having a treatment: researchers have not yet established a clinical procedure that grows new, functional follicles in a laboratory and transplants them. Today’s hair transplant surgery moves a person’s existing follicles rather than creating new ones (ISHRS patient guide).

What dermal papilla cells do in a hair follicle

The dermal papilla (DP) is a small group of specialized cells at the base of a hair follicle. It communicates with other follicle cells and helps initiate hair growth and regulate the hair cycle. DP cells are described as mesenchymal stem cell-like, but that does not mean they are ready-made replacement follicles. They are one part of a larger structure that depends on coordinated signals among different cell types (a review of stem-cell-based hair-loss treatments).

This signaling role matters in pattern hair loss. The condition involves changes in follicle signaling and progressive miniaturization; research reviewed by Tosti and colleagues describes how androgen signaling can disrupt DP-cell activity and inhibit a pathway involved in follicle growth. Hair-follicle stem cells may remain present even as hair progenitor cells are lost, so the problem is not necessarily a simple absence of all stem cells. These findings help explain why researchers are interested in restoring or influencing follicle signals, but they do not establish that DP-cell treatment can reverse hair loss in patients (the review in Advances in Stem Cell-Based Therapy for Hair Loss).

Why growing DP cells is not the same as cloning hair

In this context, “hair cloning” generally refers to the goal of producing new follicles from cells, potentially in quantities that could expand a person’s available donor supply. DP cells are of interest because of their ability to direct follicle development. However, a working follicle is a complex, organized structure—not just a collection of DP cells. Researchers would need to produce follicles that form correctly, connect with surrounding tissue, develop a blood supply, make pigmented hair, and cycle through growth and rest phases (a follicle-regeneration review).

That complexity is why cell expansion in a laboratory is not, by itself, proof of hair cloning. The research challenge is to preserve the cells’ useful signaling behavior and coordinate it with the other components needed for a functional follicle. Reviews describe several investigational regenerative approaches, including cell transplantation or micrografts, conditioned media, and cell-derived extracellular vesicles. These approaches are not interchangeable, and results from one type should not be taken as evidence that another works (a systematic review of human stem-cell use in androgenetic alopecia).

What the research can—and cannot—tell patients

Clinical studies of regenerative approaches are not the same as trials of lab-grown, cloned follicles. A 2023 systematic review covered 15 studies involving 653 participants and a range of cell-based methods (systematic review in Cells). The review reported increases in hair density across studies, but also noted limitations including small samples, varied protocols, and short follow-up. Those findings may support continued research, but they do not demonstrate that a standardized DP-cell cloning procedure is available or that results will be consistent for an individual patient (the 2023 systematic review in Cells).

At present, no stem-cell or regenerative product is FDA-approved for hair loss. There is also no established surgical procedure that creates new lab-grown follicles and transplants them; conventional FUE and FUT procedures redistribute a patient’s existing follicles. If you see “hair cloning” offered as a current treatment, ask what cells or procedure are actually involved, whether it is part of a properly overseen clinical study, and what evidence supports the claims. Registration of a facility or use of scientific language is not the same as proof of effectiveness or regulatory approval (FDA information on regenerative medicine therapies; ISHRS patient guide).

This distinction is useful when speaking with Hair Transplant Clinics or when you visit a Hair Transplant Clinic: ask whether the proposed service is a conventional transplant, an investigational cell-based approach, or a claim of follicle cloning. Request a plain-language explanation of what is being administered or transplanted and what outcomes have been studied. A reputable discussion should make clear what remains experimental rather than implying that research has already produced a dependable treatment.

Frequently Asked Questions

Are dermal papilla cells stem cells?

They are described as mesenchymal stem cell-like and play an important signaling role in follicle growth and cycling. That description does not mean that isolated DP cells can independently form a complete, transplantable hair follicle (review of stem-cell-based hair-loss treatments).

Is hair cloning available as a treatment?

No established clinical procedure currently creates new lab-grown follicles for transplantation. Current hair transplant surgery redistributes existing follicles, while follicle regeneration remains a research goal (follicle-regeneration review; ISHRS patient guide).

Could DP-cell research lead to future treatments?

It may help researchers understand how to restore or support follicle signaling, but the path from cell research to a safe, functional follicle treatment is not complete. Patients should treat claims of available hair cloning cautiously and discuss established options with a qualified medical professional.

For now, DP cells offer an important way to study how follicles grow and cycle, not a ready-made source of new hair. Hair cloning remains a research ambition, and patients should seek clear explanations of what any offered treatment actually does.